NCT05037799 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, Verzijlbergen FJ, Barrington SF, Pike LC, Weber WA, Stroobants S, Delbeke D, Donohoe KJ, Holbrook S, Graham MM, Testanera G, Hoekstra OS, Zijlstra J, Visser E, Hoekstra CJ, Pruim J, Willemsen A, Arends B, Kotzerke J, Bockisch A, Beyer T, Chiti A, Krause BJ; European Association of Nuclear Medicine (EANM)
FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015 Feb;42(2):328-54. doi: 10.1007/s00259-014-2961-x. Epub 2014 Dec 2.
de Groot EH, Post N, Boellaard R, Wagenaar NR, Willemsen AT, van Dalen JA
Optimized dose regimen for whole-body FDG-PET imaging. EJNMMI Res. 2013 Aug 12;3(1):63. doi: 10.1186/2191-219X-3-63.
Koopman D, van Osch JA, Jager PL, Tenbergen CJ, Knollema S, Slump CH, van Dalen JA
Technical note: how to determine the FDG activity for tumour PET imaging that satisfies European guidelines. EJNMMI Phys. 2016 Dec;3(1):22. doi: 10.1186/s40658-016-0158-z. Epub 2016 Sep 29.

Optimization of Image Quality for Myocardial Perfusion Imaging With Rubidium-82 PET in Patients With Known or Suspected Ischemic Heart Disease (RUBY-DOSE)

Details for clinical trial NCT05037799

Clinical trial NCT05037799 - References